Key Takeaways
- Structural separation decides who may own a pharmacy. It does not decide who may direct the pharmacist once ownership is settled, and that question belongs to the states.
- Medicine built a doctrine for this long ago. A corporation cannot practice medicine, so clinical authority rests with a physician-owned entity. Pharmacy never built the equivalent.
- No PBM should own or control a specialty pharmacy. The conflict lives in the ownership itself, and the FTC found the three largest PBMs paid their own pharmacies more on nearly every specialty generic it examined.
- Arkansas and Tennessee moved against PBM ownership, and CVS is restructuring under that pressure. Those laws reach ownership, not practice.
- Provider status raises the stakes. Once pharmacists bill the medical benefit, the employer that profits from dispensing would also control the clinical documentation and coding unless a practice standard is in place first.
Medicine established this long ago. A corporation cannot practice medicine, so clinical authority sits with a physician-owned entity regardless of who owns the building. Pharmacy has no equivalent, which leaves a chief pharmacy officer with genuine independent authority only inside an independently owned pharmacy or a pharmacist-led chain. Inside a vertically integrated PBM that owns the specialty and retail pharmacies filling its own steered scripts, that governance is opaque and unregulated, and the evidence raises real questions about collusion and misaligned incentives.
The short version. CVS is splitting its drugstores from its insurance and pharmacy benefit business, and its specialty pharmacy stays with the benefit manager. No PBM should own a specialty pharmacy, and the split leaves that problem fully intact. Breaking up ownership deals with conflicts of interest, and it leaves any owner, even a standalone drugstore chain, free to use staffing and quotas to override a pharmacist’s judgment. Most states addressed that problem for doctors decades ago with corporate practice of medicine laws. Pharmacy needs the same protection, and it needs it before pharmacists start billing health plans for clinical care at scale.
What did the CVS split actually separate?
CVS Health announced on November 4 that it plans to become two public companies by the first half of 2028, subject to board approval and a registration filing with the SEC called a Form 10. CVS Pharmacy would take roughly 9,000 retail pharmacies, mail-order pharmacy, and MinuteClinic under Prem Shah. The healthcare solutions company would keep the insurer Aetna, the pharmacy benefit manager (PBM) Caremark, CVS Specialty, Oak Street Health, and Signify Health under David Joyner, according to AJMC and Healthcare Dive.
Joyner said regulatory pressure was not the reason. Analysts pointed to the Arkansas and Tennessee PBM-pharmacy ownership laws CVS is challenging.
Earlier pieces in this series looked at how combined companies like CVS make money where their businesses hand work to each other. The split raises a question those pieces left open, which is who directs pharmacists once ownership is settled. Only a handful of states answer it at all.
Which state laws forced the question?
CVS did not move first. The states did. Arkansas enacted Act 624 in April 2025, the first law to bar a PBM from owning or operating a retail or mail-order pharmacy in the state, with a narrow exception for restricted-distribution drugs. CVS warned it would have to close 23 Arkansas pharmacies serving more than 340,000 patients, and it sued within hours of Express Scripts. In July 2025 a federal judge blocked the law on Commerce Clause grounds, with a separate preemption finding tied to TRICARE claims. The state appealed, the Eighth Circuit heard argument in September 2026, and a ruling is pending.
Tennessee went next. Governor Lee signed the FAIR Rx Act in May 2026, barring a company that owns both a PBM and a health insurer from also owning or controlling pharmacies in the state, effective July 2028. CVS warned the law could force it to close all 134 of its Tennessee locations. CVS, Express Scripts, and the PCMA each sued, raising ERISA and other federal preemption arguments that track the Arkansas challenge.
Read together, the two laws fight over the same thing, who may own the pharmacy. Arkansas bans PBM ownership outright. Tennessee targets the specific stack of PBM, insurer, and pharmacy under one parent. The CVS split answers that ownership question voluntarily at the holding-company level. Neither the laws nor the split reaches the question underneath, who may direct how the pharmacist practices once the ownership chart is redrawn. That is the ownership-practice gap, the space between who may own a pharmacy and who may direct how pharmacists practice inside it.
Figure 1. The ownership-practice gap. Ownership law decides who may hold the pharmacy. Practice law decides who may direct the pharmacist. The second column is where the current fight leaves a vacuum.
Why should no PBM own a specialty pharmacy?
Specialty pharmacies dispense high-cost drugs for conditions like cancer, multiple sclerosis, and HIV. In the split, the retail stores leave and CVS Specialty stays with Caremark. That keeps the most profitable part of dispensing inside the company that decides which pharmacies patients may use and how much those pharmacies get paid.
The FTC put numbers on that arrangement. Pharmacies affiliated with the three largest PBMs took 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016. The agency’s January 2025 staff report examined 51 specialty generic drugs from 2017 to 2022. Those affiliated pharmacies collected $7.3 billion more than pharmacies typically pay for the drugs, and more than half of the drugs studied for commercial members were marked up by over 100%, with some marked up by more than 1,000%. The PBMs also paid their own pharmacies more than unaffiliated pharmacies on nearly every specialty generic the FTC examined.
Specialty drugs are where the steering pays. They carry the highest margins, the narrowest networks, and the most discretion over where a script lands. A PBM that owns a specialty pharmacy writes the network rules and then collects on the dispensing it just steered to itself. The structural remedy is not disclosure or a firewall. It is ownership. No PBM should own or control a specialty pharmacy, because the conflict lives in the ownership itself, not in any single transaction a rule could police.
The incentives run in one direction when the same company manages the benefit and dispenses the drug.
- It decides what counts as specialty. The PBM designates which drugs are specialty drugs, and that label can route a prescription into a specialty network, often its own. Pennsylvania considered the power significant enough that Act 77 of 2024 lets pharmacies challenge a PBM’s specialty designation before the state insurance department for fully insured plans.
- It sets its own pay. The PBM decides what its pharmacy is reimbursed, and the plan sponsor pays the bill.
- It routes patients to itself. Network design and preferred-pharmacy requirements move the most profitable prescriptions in-house. The FTC said the dispensing patterns suggest exactly that.
- It profits from higher prices twice. Rebates on the benefit side and dispensing revenue on the pharmacy side both rise with list price, so no part of the company gains from a cheaper drug.
- It sits at the center of 340B contract pharmacy. Mail, specialty, and infusion pharmacies owned by the three largest PBMs hold 26% of 340B contract pharmacy relationships in 2026, according to Drug Channels Institute. Those relationships grew from 14,000 in 2020 to 62,000. Six health systems have sued CVS over 340B specialty claims since May 2026, alleging Caremark quietly paid CVS Specialty reduced rates on 340B-eligible claims. The suits together claim roughly $340 million. The claims are unproven, and CVS has said only that 340B “remains a critical program.”
- It gates its competitors. The same company runs prior authorization and network access for the rival pharmacies competing for those patients, and it sees their claims.
- It bypasses pharmacist judgment. The pharmacist inside the specialty pharmacy works for the company that also decides what is covered and what it pays.
CVS has said its clients, not Caremark, select which specialty pharmacies sit in their networks. Disclosure rules and consent orders can narrow these incentives at the margins, and only separation removes them.
If CVS’s final filing confirms this arrangement, the post-split CVS Health still owns a pharmacy, an insurer, and a PBM. That is the combination Tennessee’s FAIR Rx Act targets, and one federal structural separation would also reach.
What would the Break Up Big Medicine Act change?
The Break Up Big Medicine Act (S. 3822), introduced February 10, 2026 by Senators Warren and Hawley, is federal structural separation. As Proskauer and AJMC summarize it, the bill bars any person from owning or controlling a provider, or a management company that runs providers’ business operations, while also owning an insurer or PBM. It applies the same bar to common ownership with a drug or device wholesaler. Pharmacies fall within the bill’s definition of provider. The FTC, DOJ, HHS, state attorneys general, and private parties could enforce it, and existing arrangements would have one year to divest.
The bill was referred to Senate Judiciary, and I found no record of committee action since. A Democratic Senate in January improves its odds, though a veto still stands in the way.
Applied to the post-split CVS Health, the bill would reach CVS Specialty sitting beside Caremark and Aetna, which is the right result. Published analyses of the bill describe no provision on pharmacist staffing, productivity metrics, or professional judgment. How the remaining owner treats its pharmacists is left to state law.
Who controls pharmacist judgment once ownership is separated?
A standalone retail chain with no PBM or insurer attached still sets staffing levels, productivity metrics, and workflow rules. Those levers can override a pharmacist’s professional judgment, and the chains have used them.
In September 2023, CVS pharmacists in the Kansas City area closed as many as 22 pharmacies in two walkouts over two weeks, citing unsafe conditions tied to understaffing. CVS had announced plans earlier that year to cut or shift hours at thousands of its pharmacies. In an internal memo, CVS’s chief pharmacy officer apologized to pharmacy teams for not addressing the concerns sooner. That executive was Prem Shah, who will now run CVS Pharmacy as its own company.
None of those conditions depended on Caremark or Aetna. A retail company on thin margins, newly separated and planning a wider set of payer and PBM partnerships, will face more pressure to fill more prescriptions with fewer staff. State practice law is the tool that reaches that pressure.
The same gap shows up on the benefit side, where the operational tell is the peer-to-peer review. A PBM pharmacist gets on the line with the physician or pharmacist managing the patient, but the conversation runs on the plan’s coverage rules rather than the clinical question in front of them. The exception pathway and its documentation turn on aligning to the business rule, not on resolving the clinical issue being managed. A governance standard that vested practice authority in the pharmacist would reorder that review around the clinical need.
What is the corporate practice of pharmacy?
Control by a non-pharmacist owner over decisions that belong to a pharmacist’s professional judgment, including staffing levels, how fast prescriptions must be checked, and whether a service is safe to offer.
I call the problem the ownership-practice gap. The ownership-practice gap is the space between who may own a pharmacy and who may direct how pharmacists practice inside it. Medicine addresses its version of this gap through the corporate practice of medicine (CPOM) doctrine, a long-standing rule in many states that a business cannot direct a doctor’s medical decisions.
Roughly 33 states have some form of corporate practice of medicine regulation, according to Health Capital Consultants. MedPath counts 32 states plus the District of Columbia, and notes that classifications vary among commentators. Oregon set the current high-water mark. SB 951, signed June 9, 2025, bars management companies from practical control over clinical staffing levels, schedules, hiring and termination, diagnostic coding, clinical standards, and the prices charged for care.
Pharmacy has fragments of a doctrine and little of the substance. The AHLA’s Corporate Practice of Medicine, A Fifty State Survey (2nd ed., 2020) carries a pharmacy-specific section for only five states. Connecticut, Iowa, and Wisconsin address kickback-style fee sharing and helping unlicensed people practice. Mississippi issued pharmacy permits only to licensed pharmacists. Arizona comes closest to a judgment rule, listing as unethical conduct by the company holding a pharmacy permit “overruling or attempting to overrule a pharmacist in matters of pharmacy ethics.”
Optometry is the better precedent. It is the other licensed profession practiced inside retail chains, and states have written corporate practice rules for it since at least the 1960s. Florida bars any non-licensed entity from controlling time limits on patient examinations, the volume of patients, or the scheduling and availability of optometric services. Substitute prescriptions for patients and that rule addresses the grievances behind the 2023 walkouts.
A corporate practice of pharmacy (CPOP) standard would apply that logic to dispensing and pharmacist-delivered care. Pharmacy owners would keep control of capital, real estate, purchasing, and administration. Decisions that require a pharmacist’s professional judgment would belong to the Pharmacist Professional Corporation (PC) owner or delegated pharmacist leader.
| Federal structural separation | State CPOM | State CPOP (proposed) | |
|---|---|---|---|
| Governs | Which businesses may share an owner | Who may direct medical judgment | Who may direct pharmacist judgment |
| Instrument | Break Up Big Medicine Act (S. 3822), pending | State practice acts, case law, AG opinions | State pharmacy practice acts, board rules |
| Enforced by | FTC, DOJ, HHS, state AGs | Medical boards, state AGs | Boards of pharmacy |
| Reaches a standalone retail chain | No | Not applicable | Yes |
| Reaches a PBM-owned specialty pharmacy | Yes, through divestiture | Not applicable | Yes, through practice standards |
| Current model | No enacted federal law | Oregon SB 951 (2025) | Arizona permittee rule, California SB 362 (2021) and AB 1286 (2023), all partial |
Source. Author’s analysis. Bill provisions as summarized by Proskauer and AJMC (2026). CPOM count from Health Capital Consultants and MedPath (2025 to 2026). California provisions as summarized by Hinshaw & Culbertson (2021, 2023). Arizona rule from the AHLA fifty-state survey (2020).
Why does CPOP matter more once pharmacists bill the medical benefit?
Provider status raises the stakes. Today a chain’s staffing and productivity metrics govern dispensing. Pharmacists are working toward billing health plans for clinical services the way physicians and nurse practitioners do, under the medical benefit rather than the prescription drug benefit. Once they do, the same levers will govern which patients get a medication review, how long the visit runs, and which codes go out on the claim.
The other layers are moving. Advocates have carried the Ensuring Community Access to Pharmacist Services Act (H.R. 3164, S. 2426) in Congress. The technical work is underway. The Pharmacy Interoperability and Clinical Services Alliance (PICSA), led by Leavitt Partners, released a playbook on September 23 covering credentialing, contracting, claims configuration, documentation, and reimbursement with commercial and Medicaid plans. The CMS Health Tech Ecosystem, live since April 9, is building the data exchange that pharmacist care will run on. No comparable effort is building the governance layer.
In May I wrote that “a pharmacist billing a CPT code for a clinical judgment rendered while employed by a corporation that also profits from the downstream dispensing transaction is operating in a conflict of interest structure” (So Pharmacists Want to Be a Provider). Medicine manages that structure through CPOM and practices owned by physicians, which contract with management companies for business services. Pharmacy needs CPOP in place before clinical billing scales, or chain policy will set the documentation and coding norms for a new provider class by default. Payers credentialing pharmacists should ask what they ask of any physician group, which is who controls the clinical decision.
That structure translates directly to pharmacist clinical services. The pharmacist-owned PC holds the clinical practice. A management services organization (MSO) supports it through a management services agreement (MSA) that lists defined back-office services for a set fee. The line between the two is the governance layer pharmacy is missing.
| The pharmacist-owned PC decides | The MSO may provide under the MSA |
|---|---|
| The approved fee schedule for clinical services | Billing and claims submission against that fee schedule |
| Clinical oversight, protocols, and quality standards | EHR, IT, and data infrastructure |
| Remediation, hiring, and firing of the clinical workforce | Recruiting support, HR administration, and payroll processing |
| Compensation for pharmacists and clinical staff | Accounting and financial reporting |
| Staffing levels, clinical scheduling, and coding decisions | Scheduling systems, facilities, purchasing, and payer enrollment paperwork |
Source. Author’s framework. The reserved decisions track Oregon SB 951 (2025), which bars management companies from setting prices, making hiring and termination decisions, setting staffing levels, and making coding decisions for physician practices.
Two guardrails from dentistry carry over. Florida requires dental management fees to reasonably reflect fair market value and bars fees conditioned on patient referrals. Pharmacy MSAs need the same rules, because in a chain or PBM structure the MSO belongs to the company that profits from dispensing.
What should a state corporate practice of pharmacy law contain?
California has built the closest thing to a working model, one bill at a time. SB 362, effective January 1, 2022, bars chain community pharmacies with 75 or more California locations from imposing productivity quotas. AB 1286, effective January 1, 2024, gives the pharmacist-in-charge staffing authority and makes it unprofessional conduct to subvert a pharmacist’s exercise of professional judgment. A full standard would consolidate those pieces and borrow the rest from the corporate practice rules that medicine, dentistry, and optometry already use.
| Element from medicine | Where it already works | CPOP provision |
|---|---|---|
| No interference with judgment | Missouri bars arrangements that let an unlicensed person direct or control a licensee’s professional judgment. Indiana shields entities that do not interfere. | No owner may direct or control a pharmacist’s professional judgment. |
| A list of decisions only the clinician makes | Florida optometry reserves exam time limits, patient volume, and scheduling. Oregon SB 951 reserves staffing, schedules, and coding. | Staffing levels, the pace of prescription checks, refusal to dispense, and clinical service scheduling belong to the pharmacist-in-charge. |
| Limits on management contracts | Florida dentistry prohibits management agreements that control clinical personnel or penalize reporting violations. | Services and network contracts cannot impose quotas or fill-time guarantees, or punish reports to the board. |
| Accountability that reaches the company | Arizona treats overruling a pharmacist as unethical conduct by the permit holder. California AB 1286 extends unprofessional conduct to subverting judgment. | Board discipline reaches the permit holder and the managers who direct the conduct. |
| Bans on kickback-style fee sharing | Connecticut, Iowa, and Wisconsin pharmacy rules. | Bar compensation tied to routing patients into affiliated specialty pharmacies. |
| Hospital exceptions | Hospital employment exceptions in many CPOM states. | Hospital pharmacies under medical staff governance may be exempt. Retail, mail, and specialty pharmacies are covered. |
Source. AHLA, Corporate Practice of Medicine, A Fifty State Survey, 2nd ed. (2020), for Missouri, Indiana, Florida, Arizona, Connecticut, Iowa, and Wisconsin. Oregon and California as cited above. Rules reflect the survey’s 2020 snapshot and need a current-law check.
One element has no counterpart in medicine. Owners above a size threshold should file the productivity and workflow metrics they apply to pharmacists with the board, so enforcement does not depend on a walkout to surface the problem.
Coverage of every dispensing channel is where the two instruments meet. For specialty pharmacy, CPOP is a backstop while separation is pending. It can protect the pharmacist inside a PBM-owned specialty pharmacy, and it cannot remove the incentives that the ownership itself creates.
Erik’s Hot Take
The CVS split is a useful preview of where reform stalls if ownership is the only lever. The company kept its specialty pharmacy next to its PBM, where the FTC found the markups, and released a retail chain whose staffing practices led pharmacists to walk out in 2023. Each half now carries one of the two problems this series has described.
We need both instruments, and on specialty pharmacy the ownership answer is absolute. No PBM should own or control one. Structural separation through the FTC and DOJ addresses conflicts of interest between the payer, the PBM, and the pharmacy. A state corporate practice of pharmacy standard protects the practice itself, wherever the pharmacy sits and whoever owns it. More than 30 states already accept that a corporation should not direct a physician’s clinical judgment. Pharmacists should have the same standing, and patients gain the protection that comes with it.
State boards of pharmacy and pharmacy associations can move faster than Congress. A model act built on Oregon’s reserved-decision list, Florida’s optometry rule, and California’s quota ban would give legislators a ready text for the 2027 sessions. Retail pharmacy alone is reason enough to pass it. Specialty pharmacy and medical-benefit billing make it urgent.
Frequently asked questions
Who owns the practice of pharmacy, corporations or pharmacists?
What is the ownership-practice gap?
What is the corporate practice of pharmacy?
Why does pharmacist provider status make a corporate practice of pharmacy standard more urgent?
Should a PBM be allowed to own a specialty pharmacy?
Which states have moved against PBM ownership of pharmacies?
Does any state already prohibit the corporate practice of pharmacy?
Sources
- CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare, PR Newswire, November 4, 2026
- CVS Health to Split Retail Pharmacy From Aetna, Caremark by 2028, AJMC, November 4, 2026
- CVS to split into two companies in stunning strategic about-face, Healthcare Dive, November 4, 2026
- Judge halts Arkansas ban on PBMs owning pharmacies over Commerce Clause concerns, KATV, July 2025
- Federal judge blocks implementation of Arkansas Act 624 banning PBMs from owning pharmacies, Drug Store News, 2025
- Gov. Lee signs PBM bill CVS says could close Tennessee pharmacies, NewsChannel5, May 2026
- Express Scripts, PCMA sue to block Tennessee law breaking up PBMs and pharmacies, Healthcare Dive, 2026
- FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups, Fierce Healthcare, January 2025
- FTC Releases Second Interim Staff Report on Prescription Drug Middlemen, Federal Trade Commission, January 14, 2025
- S. 3822, Break Up Big Medicine Act, BillTrack50
- The Break Up Big Medicine Act, Potential Impacts for Healthcare Investors, Proskauer, 2026
- Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care, AJMC, 2026
- Have a complaint about CVS? So do pharmacists. Many just walked out, NPR via WUSF, September 29, 2023
- Oregon Bans Corporate Control of Physicians, Health Capital Consultants, June 2025
- CPOM Across the 50 States and D.C., MedPath, reviewed June 2026
- Oregon SB 951, Regulating the Corporate Practice of Medicine, Epstein Becker Green, June 2025
- New California Law Prohibits Chain Community Pharmacy Productivity Quotas, Hinshaw & Culbertson via JD Supra, October 2021
- California Expands No Pharmacist Left Behind, Hinshaw & Culbertson via JD Supra, November 2023
- American Health Lawyers Association, Corporate Practice of Medicine, A Fifty State Survey, 2nd ed. (2020), licensed copy
- So Pharmacists Want to Be a Provider, Erik Abel Research, May 2026
- New PICSA Playbook Offers a Roadmap for Advancing Pharmacists as Clinical Service Providers, Leavitt Partners, September 23, 2026
- Health Tech Ecosystem First Wave Launch, CMS, April 9, 2026
- FTC Releases Second Interim Staff Report, 340B contract pharmacy data, Drug Channels Institute, June 2, 2026
- CVS Health Sued Over Alleged Scheme to Siphon 340B Drug Program Savings, AJMC, May 21, 2026
- Specialty Drug Designation, Act 77, Pennsylvania Insurance Department
This piece is analysis and commentary based on public sources and professional experience as of the date noted, and nothing in it constitutes legal, clinical, or financial advice. Descriptions of pharmacy benefit, formulary, ownership, and litigation matters are general characterizations of public filings and reporting and are not directed at any specific company or plan. The 340B litigation figures are the plaintiffs’ allegations and remain unproven. Statutory and regulatory descriptions reflect the sources cited and their stated snapshot dates, and readers should confirm current law before relying on any provision. Interpretive conclusions are the author’s opinion, offered for analytical discussion. All views reflect independent professional judgment and do not represent the views or positions of any current or former employer or affiliated organization.